Vanguard Personalized Indexing Management LLC Sells 6,876 Shares of Danaher Co. (NYSE:DHR)

Vanguard Personalized Indexing Management LLC cut its holdings in Danaher Co. (NYSE:DHR - Free Report) by 14.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,560 shares of the conglomerate's stock after selling 6,876 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Danaher were worth $9,615,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in DHR. BKM Wealth Management LLC bought a new position in shares of Danaher in the 4th quarter worth about $27,000. Wetzel Investment Advisors Inc. bought a new stake in Danaher in the 4th quarter valued at about $29,000. OFI Invest Asset Management bought a new stake in Danaher in the 3rd quarter valued at about $30,000. Rakuten Securities Inc. bought a new stake in Danaher in the 4th quarter valued at about $36,000. Finally, Financial Connections Group Inc. bought a new stake in Danaher in the 4th quarter valued at about $41,000. 79.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

DHR has been the subject of a number of research analyst reports. Bank of America boosted their target price on Danaher from $258.00 to $270.00 and gave the company a "neutral" rating in a research report on Wednesday, April 24th. KeyCorp boosted their target price on Danaher from $260.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, February 1st. Barclays boosted their price objective on Danaher from $260.00 to $270.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 24th. Citigroup raised their target price on Danaher from $280.00 to $290.00 and gave the company a "buy" rating in a report on Wednesday, April 24th. Finally, TD Cowen upped their price target on Danaher from $280.00 to $290.00 and gave the stock a "buy" rating in a report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and a consensus target price of $267.31.

Danaher Stock Performance

NYSE DHR traded up $4.02 during trading hours on Wednesday, reaching $263.28. 3,072,598 shares of the company were exchanged, compared to its average volume of 2,697,800. The business's 50 day simple moving average is $248.07 and its 200-day simple moving average is $235.23. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $264.02. The stock has a market capitalization of $195.01 billion, a P/E ratio of 44.36, a P/E/G ratio of 3.87 and a beta of 0.83.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher's revenue was down 2.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.36 earnings per share. On average, equities research analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date is Friday, June 28th. Danaher's dividend payout ratio is currently 18.31%.

Insider Buying and Selling at Danaher

In other news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now owns 115,995 shares in the company, valued at $28,908,273.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Rainer Blair sold 47,175 shares of the firm's stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares of the company's stock, valued at $28,908,273.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares of the company's stock, valued at $28,304,483.16. The disclosure for this sale can be found here. Insiders have sold a total of 166,824 shares of company stock valued at $41,963,189 over the last three months. 10.90% of the stock is currently owned by insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.